23andMe (ME) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Corporate company logo of 23andMe Holding Co (ME)

23andMe Holding Co. (ME) is developing a hybrid model, combining direct sales of genetic tests with partnerships in pharmaceutical development. The company brings together leading data scientists and geneticists passionate about the concepts of personalized medicine. The stock price history reflects an EV/EBITDA ratio of . The business relies on its own product cycle, which makes it resilient to global economic fluctuations and transforms it into a defensive asset.

ME 23andMe Holding Co: Enterprise Value to EBITDA Ratio in the range 07/04/2022 - 11/14/2026

23andme.com - analytical breakdowns and key metrics (ME)

- current price and projected stock value:
Stock Price 23andMe Inc.|ME - Analyst Median Target
- market capitalization details:
Market Value 23andMe Inc|ME - Company Buyout Price
- book value of equity indicators:
Net Assets per Single Share 23andMe|ME - Company Net Assets|Market Capitalization to Book Value Ratio 23andme.com|ME - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity 23andMe Holding Co.|ME - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital 23andMe|ME - Company Aggregate Debt|Debt to Book Capitalization Ratio 23andMe Inc|ME - Company Long-Term Liabilities|Company Short-Term Debts 23andMe|Quick Liquidity Indicator 23andme.com
- business earnings and investment ratios data:
ME - Final Profit|Projected Future Earnings 23andMe Holding Co.|ME - Company Value to Net Income|Future Price to Earnings 23andMe Holding Co.|ME - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 23andMe Inc|ME - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) 23andMe|ME - Earnings per share for the last 12 months|Quarterly EPS earnings growth 23andme.com|ME - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year 23andMe Holding Co.
- sales and revenue data:
ME - Company Sales Volume|Projected Sales Volume 23andMe Inc.|ME - Price-to-Revenue Multiple|Forward Price-to-Revenue Multiple 23andMe Inc
Fundamental company valuation:ME (23andMe Inc.)
Original product of 23andme.com

The crisis of pricing power and falling demand for DNA tests at 23andMe Holding Co. (ME) make business valuation via EV/EBITDA critically important. This multiple relates the total value of the company to its operating profit before depreciation and taxes, revealing the real resilience of capital against debt. Analyzing the history of the business's EV/EBITDA ratio allows for the determination of the asset's degree of overvaluation amid deep losses and a high risk of default.

Competitors of 23andMe Holding Co. (ME)

EV/EBITDA Multiple A (Agilent Tech)|Total Company Value to Operating Income Before Depreciation Ratio Quest Corp (DGX)|ILMN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio exactsciences.com EXAS|Revvity (RVTY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Bio-Rad Laboratories, Inc.|NNNN (Anbio Tech) - EV/EBITDA Multiple|EV/EBITDA Multiple Nordion|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization QuidelOrtho (QDEL)|opko.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple CDNA (CareDx Inc)|MRVI: Enterprise Value to Operating Income Before Depreciation|FLGT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Standard BioTools Corp (LAB) - Enterprise Value to EBITDA Ratio|CTKB: EV/EBITDA Multiple|Company Value to EBITDA orasure.com (OSUR)|Enterprise Value to EBITDA Ratio XGN|MDXH: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple LUCD|PRE (prenetics.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Insight Molecular Diagnostics Inc IMDX|Trinity Biotech PLC (TRIB) - Company Value to EBITDA|PRPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AIMD: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CODX: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation HSCS|BMRA (Biomerica, Inc.) - EV/EBITDA Multiple|Cardio Diagnostics Holdings, Inc. (CDIO) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Onconetix (ONCO)|Virax Biolabs Group Limited - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BJDX (Bluejay)|Enterprise Value to EBITDA Multiple Aspira Women's Health Inc|AXDX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CNTG (Centogene)|ENZ: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Fresh2 Group|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genetic Technologies Ltd|Company Value to EBITDA Psychemedics Inc PMD